Product Description
Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25322951/)
Mechanisms of Action: MAO-b Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HNC364-A102 | P1 |
Not yet recruiting |
Parkinson's Disease |
2026-05-31 |
69% |
2025-01-30 |
Primary Endpoints |
| HNC364-A101 | P1 |
Completed |
Parkinson's Disease |
2024-04-15 |
50% |
2024-09-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CTR20250299 | P1 |
Recruiting |
Parkinson's Disease |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| CTR20231500 | P1 |
Recruiting |
Parkinson's Disease |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/05/2024 |
News Article |
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group |
|
09/04/2024 |
News Article |
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger |
|
07/22/2024 |
News Article |
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement |
|
09/26/2023 |
News Article |
Inlet Separation Device Market 2023 Demand, Growth, Research Report 2031 |